^
Association details:
| Biomarker: | EGFR wild-type |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | PF-04691502 (mTOR inhibitor, PI3K inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR
Published date:
02/22/2016
Excerpt:
The PI3K inhibitors, GSK2126458 and PF04691502, strongly inhibited the phosphorylation of Akt. These agents significantly suppressed the proliferation of wild-type EGFR A549 cells...The MEK inhibitors, AZD-8330 and TAK-733, also significantly inhibited the proliferation of A549 cells....Combined use of EGFR-TKI and MET inhibitors or inhibition of downstream signaling molecules might be a better second or third line choice for a group of patients with advanced lung cancer harboring wild-type EGFR.
DOI:
10.18632/oncotarget.7586
